CA2229024A1 - Use of fluconazole for inhibiting the growth of cancers - Google Patents

Use of fluconazole for inhibiting the growth of cancers Download PDF

Info

Publication number
CA2229024A1
CA2229024A1 CA002229024A CA2229024A CA2229024A1 CA 2229024 A1 CA2229024 A1 CA 2229024A1 CA 002229024 A CA002229024 A CA 002229024A CA 2229024 A CA2229024 A CA 2229024A CA 2229024 A1 CA2229024 A1 CA 2229024A1
Authority
CA
Canada
Prior art keywords
agents
pharmaceutical composition
triazol
propan
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002229024A
Other languages
English (en)
French (fr)
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by Individual filed Critical Individual
Publication of CA2229024A1 publication Critical patent/CA2229024A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002229024A 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers Abandoned CA2229024A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US60/001,889 1995-08-04
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections
US08/674,180 1996-07-16

Publications (1)

Publication Number Publication Date
CA2229024A1 true CA2229024A1 (en) 1997-02-20

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002229024A Abandoned CA2229024A1 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers

Country Status (18)

Country Link
EP (1) EP0841921A2 (xx)
JP (1) JPH11510187A (xx)
KR (1) KR19990036138A (xx)
CN (1) CN1195288A (xx)
AR (1) AR003175A1 (xx)
AU (1) AU711966B2 (xx)
BR (1) BR9609966A (xx)
CA (1) CA2229024A1 (xx)
CZ (1) CZ33798A3 (xx)
HU (1) HUP9903420A3 (xx)
IL (1) IL123095A0 (xx)
MX (1) MX9800998A (xx)
NO (1) NO980473L (xx)
NZ (2) NZ315184A (xx)
PL (1) PL324904A1 (xx)
SK (1) SK14198A3 (xx)
TR (2) TR199801739T2 (xx)
WO (1) WO1997005873A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (fr) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto Unite motrice susceptible d'etre accouplee a une enceinte roulante et vehicule resultant
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
KR20010103655A (ko) * 1998-11-09 2001-11-23 케네쓰 제이. 울코트 키메라 항-ｃｄ２０항체를 이용한 순환성 종양세포와관련된 혈액학적 악성종양의 치료법
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
WO2008073961A2 (en) * 2006-12-12 2008-06-19 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (nl) * 1990-11-22 1992-09-08 Mol Omer De Farmaceutische samenstelling en farmaceutische set voor het behandelen van kanker.
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
TR199800270T1 (xx) 1998-05-21
AU711966B2 (en) 1999-10-28
BR9609966A (pt) 1999-02-02
WO1997005873A3 (en) 1997-03-27
AR003175A1 (es) 1998-07-08
IL123095A0 (en) 1998-09-24
PL324904A1 (en) 1998-06-22
SK14198A3 (en) 1999-03-12
EP0841921A2 (en) 1998-05-20
AU6683396A (en) 1997-03-05
NZ503921A (en) 2002-03-01
NO980473L (no) 1998-04-03
NO980473D0 (no) 1998-02-03
MX9800998A (es) 1998-04-30
JPH11510187A (ja) 1999-09-07
KR19990036138A (ko) 1999-05-25
NZ315184A (en) 2000-05-26
HUP9903420A3 (en) 2001-12-28
TR199801739T2 (xx) 1998-12-21
WO1997005873A2 (en) 1997-02-20
CZ33798A3 (cs) 1998-06-17
CN1195288A (zh) 1998-10-07
HUP9903420A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
CA2229024A1 (en) Use of fluconazole for inhibiting the growth of cancers
AU714078B2 (en) A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers
AU714057B2 (en) A pharmaceutical composition containing N-phosphonoglycine derivatives for inhibiting the growth of viruses and cancers
AU7402998A (en) Hiv and cancer treatment
US6200992B1 (en) Pharmaceutical composition for inhibiting the growth of cancers
CA2217953C (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
CA2228503A1 (en) Use of griseofulvin for inhibiting the growth of cancers
US5908855A (en) Compositions for treating viral infections
MXPA98000998A (en) Use of fluconazole to inhibit the growth of cance
MXPA97007809A (en) A pharmaceutical composition containing benzymidazole to inhibit the growth of cance
MXPA98000944A (es) Uso de derivados de 1h-1,2,4-triazol para inhibirel crecimiento de canceres
Young et al. Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer
Little et al. Programmed cell death in the anuran tadpole tail requires expression of a cell surface glycoprotein
AU3879001A (en) Hiv and cancer treatment
JPS60184018A (ja) 抗原虫剤
AU2231500A (en) A pharmaceutical composition containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
MXPA97007810A (es) Una composicion farmaceutica que contiene derivados de n-fosfonoglicina para inhibir el crecimientode virus y canceres

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued